A qualitative review of neoadjuvant chemotherapy in resectable pancreatic adenocarcinoma

Alex B. Blair, Rebecca Sorber, Noah S. Rozich, Richard A. Burkhart

Research output: Contribution to journalReview article


The aim of this study was to evaluate outcomes of patients with resectable pancreatic adenocarcinoma (PDAC) who underwent neoadjuvant chemotherapy. The MEDLINE and PubMed databases were searched to identify relevant original articles investigating neoadjuvant therapy in resectable PDAC. Qualitative analyses were performed to investigate patient selection, disease stage, impact on perioperative outcomes, and cost-effectiveness. Forty-three studies met inclusion criteria for this review. Neoadjuvant chemotherapy for upfront resectable PDAC is cost-effective, safe, may result in lower stage disease and has potential survival advantages. With proper patient selection, neoadjuvant chemotherapy is an appropriate approach for upfront resectable PDAC. Nevertheless, the risk for disease progression and losing a curative surgical window highlights the need for appropriate patient identification, further discovery of superior biomarkers or molecular profiles representative of positive treatment response, and additional prospective comparative study.

Original languageEnglish (US)
Pages (from-to)973-984
Number of pages12
Issue number8
StatePublished - Sep 1 2019


  • neoadjuvant therapy
  • pancreatic neoplasms
  • preoperative chemotherapy
  • resectable pancreatic cancer
  • upfront resectable

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Fingerprint Dive into the research topics of 'A qualitative review of neoadjuvant chemotherapy in resectable pancreatic adenocarcinoma'. Together they form a unique fingerprint.

  • Cite this